Update on alisporivir in treatment of viral hepatitis C

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

(2011) Michael Manns et al.   ANTIVIRAL THERAPY

Treatment implication from the potential association between nonalcoholic fatty liver disease and cardiovascular disease

(2011) Liang Shen   HEPATOLOGY

4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS

(2011) R. Flisiak et al.   JOURNAL OF HEPATOLOGY

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

(2011) S. Zeuzem et al.   JOURNAL OF HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2011)   JOURNAL OF HEPATOLOGY

The global health burden of hepatitis C virus infection

(2011) Francesco Negro et al.   LIVER INTERNATIONAL

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

(2011) Markus Cornberg et al.   LIVER INTERNATIONAL

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025

(2010) Isabelle Landrieu et al.   BIOCHEMISTRY

Evolving epidemiology of hepatitis C virus

(2010) D. Lavanchy   CLINICAL MICROBIOLOGY AND INFECTION

Sustained virological response with 29 days of Debio 025 monotherapy in hepatitis C virus genotype 3

(2010) H. Patel et al.   GUT

755 SUSTAINED VIROLOGICAL RESPONSE AFTER 4-WEEK TREATMENT WITH DEBIO 025 MONOTHERAPY OR COADMINISTERED WITH PEG-IFNα2A IN HCV GENOTYPE 1 AND 3 PATIENTS

(2010) A. Horban et al.   JOURNAL OF HEPATOLOGY

HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A–cyclophilin A interaction to cyclophilin inhibitors

(2010) Udayan Chatterji et al.   JOURNAL OF HEPATOLOGY

Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A

(2010) Fiona Fernandes et al.   PLoS One

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A

(2010) Lotte Coelmont et al.   PLoS One

An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C

(2009) Raf Crabbé et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients

(2009) Robert Flisiak et al.   HEPATOLOGY

Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A

(2009) Sandra Ciesek et al.   HEPATOLOGY

The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication

(2009) Udayan Chatterji et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

946 PK-PD MODELING OF VIRAL KINETICS DURING TREATMENT WITH DEBIO-025 PLUS PEGYLATED INTERFERON ALPHA-2A IN TREATMENT-NAIVE HCV PATIENTS

(2009) E. Herrmann et al.   JOURNAL OF HEPATOLOGY

95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS

(2009) D.R. Nelson et al.   JOURNAL OF HEPATOLOGY

Multiple cyclophilins involved in different cellular pathways mediate HCV replication

(2009) L. Alex Gaither et al.   VIROLOGY

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus

(2008) Robert Flisiak et al.   HEPATOLOGY

Cyclophilin A Is an Essential Cofactor for Hepatitis C Virus Infection and the Principal Mediator of Cyclosporine Resistance In Vitro

(2008) F. Yang et al.   JOURNAL OF VIROLOGY

Interferon-based therapy for chronic hepatitis C: current and future perspectives

(2008) Stefan Zeuzem   Nature clinical practice. Gastroenterology & hepatology